In chronic renal failure, substances that are effectively excreted in healthy subjects accumulate in serum. These substances, uremic toxins, include a variety of organic acids. It has been reported that a decrease in the bilirubin (BR) binding capacity occurs in the serum of renal failure patients. 3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) has a high affinity for human serum albumin (HSA) and is a potent inhibitor of the serum protein binding of many drugs. We recently reported that CMPF and BR share the binding site for dicarboxylate molecules on the HSA molecule [Pharm Res 1999;16:916–923]. In this study, in order to confirm whether CMPF is involved in the decrease of BR serum binding capacity in chronic renal failure patients, the total concentrations of uremic toxins, CMPF, and indoxyl sulfate (IS) and the free BR concentration in serum from healthy volunteers and renal failure patients were determined. Both total CMPF and IS concentrations correlate with the free BR concentration. However, results from the peroxidase method reveal that IS cannot displace BR under the physiological condition [IS]/[HSA] <1. We, therefore, conclude that CMPF is one of the substances which contribute to the decreased binding capacity of BR in uremic serum.

Keywords:
3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid, Bilirubin, Human serum albumin, Chronic renal failure, Protein binding
1.
Sakai T, Takadate A, Otagiri M: Characterization of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 1995;18:1755–1761.
2.
Niwa T, Yazawa T, Kodama T, Uehara Y, Maeda K, Yamada K: Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 1990;56:241–245.
3.
Lim C-F, Bernard B, Jong M, Doctor R, Krenning E, Hennemann G: A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993;76:318–324.
4.
Costigan M, Callaghan C, Lindup WE: Hypothesis: Is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron 1996;73:169–173.
5.
Niwa T, Aiuchi T, Nakaya E, Emoto Y, Miyazaki T, Maeda K: Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. Clin Nephrol 1993;39:92–96.
6.
Niwa T, Takeda N, Nakaya K, Shibata M, Tatematsu A: Accumulation of furandicarboxylic acids in uremic serum as inhibitors of drug binding. Clin Chim Acta 1988;173:127–138.
7.
Mabuchi H, Nakahashi H, Hamajima T, Aikawa I, Oka T: The effect of renal transplantation on a major endogenous ligand retained in uremic serum. Am J Kidney Dis 1989;13:49–54.
8.
Brodersen R: Bilirubin: Solubility and interaction with albumin and phospholipid. J Biol Chem 1979;254:2364–2369.
9.
Øie S, Lowenthal D, Levy G: Protein binding of bilirubin in plasma of anephric patients. J Dial 1980;4:91–100.
10.
Tsutsumi Y, Maruyama T, Takadate A, Goto M, Matsunaga H, Otagiri M: Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin. Pharm Res 1999;16:916–923.
11.
Chen R: Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 1967;242:173–181.
12.
Brodersen R: Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation. J Clin Invest 1974;54:1353–1364.
13.
Jacobsen J, Fedders O: Determination of non-albumin-bound bilirubin in human serum. Scand J Clin Lab Invest 1970;26:237–241.
14.
Shaklai N, Garlick R, Bunn H: Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J Biol Chem 1984;269:3812–3817.
15.
Meucci E, Mordente A, Martorana G: Metal-catalyzed oxidation of human serum albumin: Conformational and functional changes. Implications in protein aging. J Biol Chem 1991;266:4692–4699.
16.
Takamura N, Maruyama T, Otagiri M: Effects of uremic toxins and fatty acids on protein binding of furosemide: Possible mechanism of the binding defect in uremia. Clin Chem 1997;43:2274–2280.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.